Table 1. General characteristics of the enrolled studies.
| Author | Year | Country | Study design | Number | Intervention | Age | Weight / BMI | Duration of prevention | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treatment | Comparator | Treatment | Comparator | Treatment | Comparator | ||||||
| Burrows RF[13] | 2001 | Australia | RCT | 76 | dalteparin 2500 IU (n = 39) |
Saline (n = 37) |
31.7±4.8 | 31.3±5.5 | 81.7[17.2] | 79.9[14.0] | 5 days |
| Ellison J[14] | 2001 | United Kingdom | RCT | 30* | enoxaparin 4000 IU (n = 10) tinzaparin 50 IU/kg (n = 10) dalteparin 5000 IU (n = 10) |
NR | 26(18–35) 27(16–42) 28(16–40) |
NR | BMI 28.2(22–41) 29.5(21–40.7) 27.8(23–39) |
NR | 5 days |
| Farjah A[15] | 2012 | K.S.A. | RCT | 300 | tinzaparin 4500 IU (n = 100) |
Placebo (n = 200) |
28.6 (18–35) | 28.6 (18–35) | NR | NR | 14 days |
| Gates S[16] | 2004 | United Kingdom | RCT | 141 | enoxaparin 40 mg (n = 70) |
saline (n = 71) |
31.3±5.8 | 30.6±5.4 | ≥80 kg, 29% | ≥80 kg, 30% | 14 days |
| Gibson J L[17] | 1998 | United Kingdom | RCT | 17* | enoxaparin 20 mg (n = 6) enoxaparin 40 mg (n = 5) |
UFH 7500IU ×2 (n = 6) |
NR | NR | NR | NR | NR |
| Gizzo S[19] | 2014 | Italy | Prospective Cohort | 529 | enoxaparin 4000 UI or dalteparin 5000 UI (n = 349) |
no treatment (n = 180) |
38.07±2.58 | 38.3±2.77 | BMI 27.14±2.16 |
BMI 27.48±1.93 |
7 days |
| Heilmann L[18] | 2007 | Germany | RCT | 150 | dalteparin 5000 U (n = 50) UFH 5000 IU×2 (n = 50) |
no treatment (n = 50) |
28±6 29±5 |
28±3 | BMI 23±4 23±2 |
BMI 20±7 |
7 days |
Abbreviations: *, in addition to CS, there was at least one additional risk factor for thrombosis